SNY Jan 2025 20.000 call
| Previous close | 32.74 |
| Open | 32.70 |
| Bid | 32.00 |
| Ask | 36.50 |
| Strike | 20.00 |
| Expiry date | 2025-01-17 |
| Day's range | 32.20 - 32.74 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo FinanceAmazon Health: A long play and a search for partners
Amazon Pharmacy is just one of the segments of health that the e-retail giant is pursuing.
ZacksFDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE
If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.
GlobeNewswirePress Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review If approved, Dupixent would be the first and only treatment indicated in the U.S. for children aged 1- 11 with eosinophilic esophagitis, a disease driven by type 2 inflammation that impacts the ability to eatOf the approximately 21,000 children under the age of 12 in the U.S. currently being treated for EoE, about 9,000 do not satisfactorily respond to the unapproved the
